The healthcare security bureaus of Anhui and Qinghai provinces in China have separately released notifications regarding the adjustment of the basic medical insurance (BMI) chronic disease drug lists for outpatients. These lists are significant as they often result in improved reimbursement conditions for patients and can lead to certain drugs being exempted from hospital budget caps, enhancing accessibility to necessary medications.
Anhui’s Expanded Chronic Disease Drug List
Anhui’s updated list includes 144 varieties covering 69 disease areas. Notably, 78 of these drugs are part of the renewal negotiations for the 2022 National Reimbursement Drug List (NRDL), and 13 are included via price bidding in the NRDL. The leading three targeted disease areas are malignant tumors with 27 varieties, coronary heart disease with 15 varieties, and HIV/AIDS with 13 varieties. The list also saw the removal of 17 drugs, which included treatments for ulcerative colitis, Crohn’s disease, hyperthyroidism, and malignant tumors.
Qinghai’s Updated Chronic Disease Drug List and Its Impact
Qinghai’s list features 72 new entrants across 19 disease areas. It includes 56 varieties with renewal statuses and 8 drugs added through price bidding. The primary disease targets are malignant tumors with 19 varieties, chronic renal failure with 17 varieties, and diabetes with 12 varieties. Traditional Chinese medicine Lianbizhi Injection, aimed at chronic pulmonary heart disease, and hypertension therapy febuxostat were removed from the list.-Fineline Info & Tech
